Establish the PK of Belinostat in Patients With Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes
Phase 1 Completed
17 enrolled
Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer
Phase 1 Completed
26 enrolled
Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat Trials
Phase 1 Completed
8 enrolled
PTCL
Phase 2 Completed
129 enrolled 12 charts
MTD Study PXD-101 in Combination With Paclitaxel + Carboplatin in Chemotherapy-Naive Patients With Stage IV NSCLC
Phase 1/2 Completed
23 enrolled
Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer
Phase 1 Completed
6 enrolled
Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)
Phase 1 Completed
23 enrolled
Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin
Phase 2 Completed
29 enrolled 9 charts
Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction
Phase 1 Completed
72 enrolled 23 charts
A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers
Phase 1 Completed
28 enrolled
Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL
Phase 2 Completed
5 enrolled 8 charts
Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors
Phase 2 Completed
32 enrolled 11 charts
PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery
Phase 2 Completed
13 enrolled 7 charts
PXD101 in Treating Patients With Acute Myeloid Leukemia
Phase 2 Completed
12 enrolled 6 charts
Belinostat and Isotretinoin in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery
Phase 1 Completed
51 enrolled
Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
Phase 1/2 Completed
54 enrolled 8 charts
Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome
Phase 1 Completed
41 enrolled
Belinostat (PXD101) to Treat Tumors of the Thymus at an Advanced Stage
Phase 2 Completed
41 enrolled 8 charts
A Study of Belinostat in Combination With Warfarin in Patients With Solid Tumors or Hematological Malignancies
Phase 1 Completed
27 enrolled
A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment
Phase 1/2 Completed
80 enrolled 19 charts
Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary
Phase 2 Completed
89 enrolled 12 charts
A Phase I/II Clinical Trial of PXD101 in Combination With Doxorubicin in Patients With Soft Tissue Sarcomas
Phase 1/2 Completed
41 enrolled 18 charts
Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
Phase 2 Completed
25 enrolled
Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma
Phase 1 Completed
121 enrolled
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors
Phase 1 Completed
35 enrolled
Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases
Phase 1 Completed
56 enrolled
PXD101 in Treating Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
Phase 2 Completed
22 enrolled 8 charts
PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
Phase 1 Completed
55 enrolled